E203K Mutation in MAP2K1 (MEK1) Causes Resistance to PD-1 Blockade and Responds to Trametinib in Epstein-Barr Virus Associated Gastric Cancer
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP338974
下载链接
链接失效反馈官方服务：
资源简介：
Epstein-Barr virus associated gastric cancer (EBVaGC) is characterized by higher lymphocytic infiltration, predicting sensitivity to immunotherapy. However, no clinical data is available to investigate its acquired resistance. We describe a patient with EBVaGC underwent acquired resistance to PD-1 blockade after partial response by chemotherapy plus sintilimab, a fully humanized anti-PD-1 monoclonal antibody. Re-biopsy revealed a secondary gain-of-function mutation in diver gene MAP2K1/MEK1 (E203K) was acquired.
创建时间：
2021-10-01
